Publications

J Clin Invest. 2018; 128(10): 4654–4668.

Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade

British Journal of Cancer. 2018; 118: 9–16.

Mechanisms of resistance to immune checkpoint inhibitors

Nature Communications. 2017; 8: 1136.

Resistance to checkpoint blockade therapy through inactivation of antigen presentation

Blood. 2020; 135 (6): 399–410.

Pluripotent stem cell–derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity

2019 ASH Abstract

FT596: Translation of First-of-Kind Multi-Antigen Targeted Off-the-Shelf CAR-NK Cell with Engineered Persistence for the Treatment of B Cell Malignancies

New England Journal of Medicine. 2020; 382: 545–53.

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

2019 ASH Abstract

FT538: Preclinical Development of an Off-the-Shelf Adoptive NK Cell Immunotherapy with Targeted Disruption of CD38 to Prevent Anti-CD38 Antibody-Mediated Fratricide and Enhance ADCC in Multiple Myeloma When Combined with Daratumumab

2019 ASH Abstract

FT576: A Novel Multiplexed Engineered Off-the-Shelf Natural Killer Cell Immunotherapy for the Dual-Targeting of CD38 and BCMA for the Treatment of Multiple Myeloma

2019 ASH Abstract

FT819: Translation of Off-the-Shelf TCR-Less Trac-1XX CAR-T Cells in Support of First-of-Kind Phase I Clinical Trial

Nature Medicine. 2019; 25: 82–88.

Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency

Nature. 2017; 543: 113–117.

Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection

Stem Cell Reports

Platform for Induction and Maintenance of Transgene-free hiPSCs Resembling Ground State Pluripotent Stem Cells